Aeolus Pharmaceuticals, Inc. is a pharmaceutical company, which engages in developing a portfolio of novel metalloporphyrins. The company is headquartered in Mission Viejo, California and currently employs 4 full-time employees. The firm focuses on developing a platform of compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. As of September 30, 2016, the Company's platform consisted of approximately 180 compounds licensed from the University of Colorado (UC), Duke University (Duke) and National Jewish Health (NJH). The firm's lead compound is AEOL 10150, which is being developed as a medical countermeasure (MCM) against the pulmonary sub-syndrome of acute radiation syndrome (Pulmonary Acute Radiation Syndrome or Lung-ARS) and the delayed effects of acute radiation exposure (DEARE). Its other product is AEOL 11114 and AEOL 20415. AEOL 10150 is indicated for the treatment of radiation oncology and idiopathic pulmonary fibrosis. AEOL 11114 is indicated for the treatment of Parkinson's disease and epilepsy. AEOL 20415 is an orally-available, anti-infective compound.
Follow-Up Questions
Hiệu suất giá của cổ phiếu AOLS như thế nào?
Giá hiện tại của AOLS là $0.0001, đã decreased 0% trong ngày giao dịch cuối cùng.
Chủ đề kinh doanh chính hoặc ngành của Aeolus Pharmaceuticals Inc là gì?
Aeolus Pharmaceuticals Inc thuộc ngành Pharmaceuticals và lĩnh vực là Health Care
Vốn hóa thị trường của Aeolus Pharmaceuticals Inc là bao nhiêu?
Vốn hóa thị trường hiện tại của Aeolus Pharmaceuticals Inc là $15209
